Recombinant Newcastle disease virus as a vaccine vector
/in International Publications, Newcastle Disease Virus /von 2003-06-01 / Poult. Sci. 2003 Jun;82(6):899-906Immunotherapy for lymphomas
/in International Publications, Malignant Lymphoma /von 2003-06-01 / Int. J. Hematol. 2003 Jun;77(5):444-55Doxorubicin activity is enhanced by hyperthermia in a model of ex vivo vascular perfusion of human colon carcinoma
/in Colorectal Cancer, Hyperthermia, International Publications /von 2003-05-13 / World J Surg 2003 Jun;27(6):640-6Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2003-05-01 / Trends Endocrinol. Metab. 2003 May-Jun;14(4):156-62Dendritic cell-based immunotherapy for the treatment of hematological malignancies
/in Acute Leukemia, Dendritic Cells, International Publications, Multiple Myeloma /von 2003-04-01 / Hematology 2003 Apr;8(2):97-104[Clinical research on the treatment effect of autologous dendritic cell vaccine on the patients with chronic hepatitis B]
/in Chronic Virus Hepatitis, International Publications /von 2003-04-01 / Zhonghua Gan Zang Bing Za Zhi 2003 Apr;11(4):206-8TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients
/in International Publications, Ovarian Cancer /von 2003-04-01 / Clin. Cancer Res. 2003 Apr;9(4):1517-27Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract
/in Colorectal Cancer, International Publications /von 2003-03-01 / World J. Gastroenterol. 2003 Mar;9(3):495-8In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells
/in International Publications, Pancreatic Cancer /von 2003-03-01 / Int. J. Oncol. 2003 Mar;22(3):651-6
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution